Abstract
Purpose Non-invasive urine-based biomarkers for bladder cancer (BC) diagnosis and surveillance can potentially improve current diagnostic and monitoring protocols by guiding cystoscopy. Here, we aim to access the diagnostic performance of nomograms based on published biomarker panels for BC detection (BC-116) and monitoring of recurrence (BC-106) in combination with cytology, in two prospectively collected patient cohorts.
Experimental Design 602 recruited patients were screened for presence of BC, out of which 551 were found eligible for further analysis. For the primary setting, urine samples from 73 eligible patients were analyzed from those diagnosed with primary BC (n=27) and benign urological disorders (n=46). For the surveillance setting, 478 eligible patients were considered (83 BC recurrences; 395 negative for recurrence). Urine samples were analyzed with capillary electrophoresis coupled to mass spectrometry and the biomarker score was estimated via a support vector machine-based software.
Results Validation of the BC-116 biomarker panel resulted in 89% sensitivity and 67% specificity (AUCBC-116=0.82), similar to the published estimates. The nomogram based on cytology and BC-116 resulted in good (AUCNom116=0.85) but not significantly better performance than the BC-116 alone (P=0.5672). BC-106 biomarker panel showed 89% sensitivity and 32% specificity for surveillance, while improved performance was achieved when a nomogram including BC-106 and cytology was evaluated (AUCNom106=0.82), significantly outperforming both cytology (AUCcyt=0.72;P=0.0022) and BC-106 alone (AUCBC-106=0.67;P=0.0012).
Conclusions BC-116 biomarker panel is a useful test for detecting primary BC. BC-106 classifier integrated with cytology and showing >95% negative predictive value, might be useful for decreasing the number of cystoscopies during surveillance.
Competing Interest Statement
H.M. holds ownership interest in Mosaiques Diagnostics GmbH. M.F. and M.M. are employed by Mosaiques Diagnostics GmbH. No potential conflicts of interest were disclosed by the other authors.
Funding Statement
This work was supported in part by BioMedBC (752755; H2020-MSCA-IF-2016), funded by the European Commission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the Declaration of Helsinki and ethical approval was obtained by local Ethics Committees. Informed consent processes adhered to Institutional Review Board-approved guidelines. Ethical approval for this study was obtained by the Ethics Committee in Medical School of Hannover (ID: 3274-2016).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: This work was supported by BioMedBC (752755; H2020-MSCA-IF-2016), funded by the European Commission.
Conflict of interest: H.M. holds ownership interest in Mosaiques Diagnostics GmbH. M.F. and M.M. are employed by Mosaiques Diagnostics GmbH. No potential conflicts of interest were disclosed by the other authors.
Translational Relevance Bladder cancer (BC) has the highest lifetime cost per patient among all cancers due to the high recurrence rate and the need for a long-term patient monitoring. Several urinary biomarkers have been identified in recent years for BC detection and monitoring. However, reaching a diagnostic accuracy sufficient for clinical implementation is challenging. A pilot comparison showed complementarity between cytology and two previously reported urinary biomarker panels for BC detection (BC-116) and surveillance (BC-106). Considering this hypothesis, here we present a prospective multicenter study aiming to evaluate diagnostic nomograms integrating cytology and the biomarker panels in 602 patients screened for primary and recurrent BC. Overall, the nomogram including cytology and BC-116 panel demonstrated good performance but similar to BC-116 alone, in primary BC detection. Notably, the nomogram including BC-106 panel and cytology showed added value and could be potentially applied for BC surveillance by reducing the average number of follow-up cystoscopies.
Data Availability
All data produced in the present study are available from the corresponding author upon reasonable request.